Developments in cystic fibrosis personalised epithelial assays: Science and patient perspectives.

J Cyst Fibros

Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and the University of Newcastle, Newcastle, NSW, Australia; Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia.

Published: May 2018

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcf.2018.03.012DOI Listing

Publication Analysis

Top Keywords

developments cystic
4
cystic fibrosis
4
fibrosis personalised
4
personalised epithelial
4
epithelial assays
4
assays science
4
science patient
4
patient perspectives
4
developments
1
fibrosis
1

Similar Publications

The issue of a possible association between Shwachman-Diamond Syndrome and diabetes has been debated for many years. This review updates the Italian Shwachman-Diamond registry, confirming our previous findings that suggest that these patients might be at higher risk of developing diabetes, particularly type 1. These data are of relevance in the clinical follow-up of patients in everyday life, emphasizing the need for early diagnosis and timely intervention.

View Article and Find Full Text PDF

Background And Aims: Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset < 6 years, can present with severe manifestations and may require biologic therapy. Infliximab and adalimumab are approved for induction and maintenance in pediatric IBD patients but are licensed only above the age of 6 years. Effectiveness and safety data on adalimumab in this patient population are lacking.

View Article and Find Full Text PDF

Background: Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are prevalent disease complications in people with cystic fibrosis. These understudied comorbidities significantly impact quality of life. The impact of highly effective modulator therapy (HEMT) in young children with cystic fibrosis (YCwCF) on these disease complications is unknown.

View Article and Find Full Text PDF

[Controlling cystic echinococcosis: outlook in the 21st centuryControle da equinococose/hidatidose cística: perspectivas no século XXI].

Rev Panam Salud Publica

January 2025

Centro Panamericano de Fiebre Aftosa Unidad de Salud Pública Veterinaria Organización Panamericana de la Salud Río de Janeiro Brasil Centro Panamericano de Fiebre Aftosa, Unidad de Salud Pública Veterinaria, Organización Panamericana de la Salud, Río de Janeiro, Brasil.

Cystic echinococcosis (CE) is a serious public health problem in South America, one that the Pan American Health Organization (PAHO) has included in its Plan of Action for the Control of Neglected Infectious Diseases. A logical framework for CE control was defined: this includes establishing the objective to be achieved (eradication or elimination as a public health problem) and determining levels of endemicity which serve as a guide for establishing frequencies of intervention (high endemicity, endemic, and low endemicity, according to rates in the different hosts). There are two validated tools for CE control: systematic deworming of dogs using praziquantel (PZQ) and systematic vaccination of sheep with recombinant EG95 protein, or a combination of both tools.

View Article and Find Full Text PDF

Introduction: Duplication of the gallbladder is a rare congenital malformation associated with the development of cholelithiasis. It increases the risk of iatrogenic bile duct injury during cholecystectomy and can lead to symptom recurrence if missed. Although preoperative imaging is helpful, detection rates are around 50 %.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!